Friday, March 18, 2022

APYX Sees 3-30% Revenue Growth, AVDL Awaits FDA Decision, KZR To Report MISSION Data In Q2...

Kezar Life Sciences Inc (KZR) has a couple of catalysts to watch in the coming months. Topline data from its MISSION and PRESIDIO trials are expected in the second quarter of this year. Will Kezar accomplish its mission?

from RTT - Earnings https://ift.tt/2sT3lId
via IFTTT

No comments:

Post a Comment